Literature DB >> 28562205

Diameter of the Pulmonary Artery in Relation to the Ascending Aorta: Association with Cardiovascular Outcome.

Andreas A Kammerlander1, Stefan Aschauer1, Caroline Zotter-Tufaro1, Franz Duca1, Klaus Knechtelsdorfer1, Matthias Wiesinger1, Marianne L Schwaiger1, Daniel Dalos1, Matthias Schneider1, Beatrice A Marzluf1, Diana Bonderman1, Julia Mascherbauer1.   

Abstract

Purpose To investigate whether the pulmonary artery (PA)-to-ascending aorta (Ao) ratio is associated with outcome in unselected patients referred for cardiac magnetic resonance (MR) imaging. Materials and Methods This study prospectively enrolled 650 consecutive patients (47.2% women; mean age, 56.1 years ± 17.7 [standard deviation]). Diameters of PA and Ao were measured in axial black blood images. On the basis of previous results, a PA-to-Ao ratio of 1.0 or greater was chosen as the cutoff for further analysis. Univariable and multivariable Cox regression models were used to investigate the primary end point, which was defined as a composite of cardiovascular hospitalization and death. Results A PA-to-Ao ratio of 1.0 or greater was present in 131 (20.2%) patients. Patients with a PA-to-Ao ratio of 1.0 or greater were predominantly women (P = .010); more frequently presented with atrial fibrillation (P < .001), diabetes (P < .001), and impaired renal function (P < .001); and had higher N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (P < .001), larger left (P = .023) and right ventricles (RV; P = .002), and worse RV function (P < .001). Patients were followed for 17.8 months ± 12.9, during which 110 patients (16.9%) reached the primary end point. By Kaplan-Meier analysis, event-free survival was significantly worse in patients with a PA-to-Ao ratio of 1.0 or greater (log-rank test, P < .001). A PA-to-Ao ratio of 1.0 or greater was independently associated with outcome by multivariable Cox regression analysis, in addition to age, NT-proBNP serum levels, and RV size. Conclusion A PA-to-Ao ratio of 1.0 or greater identified patients at risk, most likely because of elevated PA pressures. On the basis of these results, the PA-to-Ao ratio should routinely be reported at cardiac MR imaging. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2017        PMID: 28562205     DOI: 10.1148/radiol.2017161849

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

1.  Epicardial fat volume measured on nongated chest CT is a predictor of coronary artery disease.

Authors:  Yasunori Nagayama; Naoki Nakamura; Ryo Itatani; Seitaro Oda; Shinichiro Kusunoki; Hideo Takahashi; Takeshi Nakaura; Daisuke Utsunomiya; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2019-03-11       Impact factor: 5.315

2.  Association between Large Arteries Diameter and Heart Function in Subjects Free of Cardiovascular Diseases.

Authors:  Ricarda von Krüchten; Roberto Lorbeer; Annette Peters; Fabian Bamberg; Christopher L Schlett; Blerim Mujaj
Journal:  J Pers Med       Date:  2022-05-28

3.  Predicting Atrial Fibrillation from Automated Measurements of Left Atrial Volume Using Routine Chest CT Examination: Overlooked and Underrecognized Risk Factors.

Authors:  Albert de Roos; Qian Tao
Journal:  Radiol Cardiothorac Imaging       Date:  2019-12-19

4.  Larger pulmonary artery to ascending aorta ratios are associated with decreased survival of patients undergoing pulmonary endarterectomy.

Authors:  Panja M Boehm; Stefan Schwarz; Jürgen Thanner; Cecilia Veraar; Mario Gerges; Christian Gerges; Irene Lang; Paul Apfaltrer; Helmut Prosch; Shahrokh Taghavi; Walter Klepetko; Hendrik Jan Ankersmit; Bernhard Moser
Journal:  JTCVS Open       Date:  2022-02-23

5.  Impact of Systemic Volume Status on Cardiac Magnetic Resonance T1 Mapping.

Authors:  Marlies Antlanger; Stefan Aschauer; Andreas A Kammerlander; Franz Duca; Marcus D Säemann; Diana Bonderman; Julia Mascherbauer
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.